Targeting the CD47-SIRPα axis can enhance the phagocytic capacity of macrophages, thereby augmenting their antigen burden and amplifying the presentation of antigens to T cells.402 This approach has the advantage of simultaneously boosting the immune system’s capacity to identify and eradicate tumor cells. This evidence concerns the gene SIRPA and neoplasm.